A securities class action lawsuit has been filed against Corcept Therapeutics Incorporated and certain executives in the U.S. District Court for the Northern District of California. The suit seeks to recover investor losses tied to purchases of Corcept common stock between October 31, 2024, and December 30, 2025, alleging the company misled the market about the regulatory prospects for its drug candidate relacorilant despite reported FDA warnings that the clinical data was inadequate. The complaint points to a sharp share-price drop after Corcept disclosed on December 31, 2025 that it received a Complete Response Letter from the FDA, and notes an April 21, 2026 deadline to seek lead plaintiff status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603041328PRIMZONEFULLFEED9665881) on March 04, 2026, and is solely responsible for the information contained therein.